Brokers Offer Predictions for PBLS Q3 Earnings

Key Points

• HC Wainwright expects Parabilis Medicines to report a Q3 2026 loss of $0.35 per share and maintains a “Buy” rating with a $40 price target. Analysts’ estimates indicate losses narrowing from $2.10 per share in fiscal 2026 to $1.55 in fiscal 2027.
• Parabilis’ analyst consensus is a “Moderate Buy” with an average price target of $41.25, although the company recently posted a $2.32-per-share loss—far worse than the $0.16 consensus estimate—and generated only $0.15 million in revenue.
• Recent clinical and regulatory developments are positive: the company reported encouraging Phase 1/2 desmoid-tumor results and plans to begin a placebo-controlled Phase 3 trial in the first half of 2027. However, investors face substantial execution, funding and regulatory risks, with topline Phase 3 results not expected until 2029.

Parabilis Medicines, Inc. (NASDAQ:PBLS - Free Report) - Investment analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Parabilis Medicines in a research report issued to clients and investors on Thursday, October 22nd. HC Wainwright analyst R. Burns expects that the company will post earnings of ($0.35) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Parabilis Medicines' current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Parabilis Medicines' Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($2.10) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.55) EPS.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The company had revenue of $0.15 million for the quarter.

Other analysts have also recently issued research reports about the stock. Guggenheim initiated coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They issued a "buy" rating and a $40.00 price target for the company. Lifesci Capital raised shares of Parabilis Medicines to a "strong-buy" rating in a research report on Monday, July 6th. Weiss Ratings upgraded Parabilis Medicines from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, October 16th. Leerink Partners assumed coverage on Parabilis Medicines in a report on Monday, July 6th. They issued an "outperform" rating and a $40.00 price objective on the stock. Finally, Zacks Research upgraded Parabilis Medicines to a "hold" rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.25.

Parabilis Medicines Price Performance

NASDAQ:PBLS opened at $24.44 on Monday. The firm has a market cap of $3.02 billion and a price-to-earnings ratio of -11.47. The company has a 50-day moving average price of $34.18. Parabilis Medicines has a 1-year low of $22.66 and a 1-year high of $42.49.

Institutional Trading of Parabilis Medicines

Several institutional investors have recently added to or reduced their stakes in PBLS. Sterling Capital Management LLC acquired a new position in Parabilis Medicines during the third quarter worth $35,000. WINTON GROUP Ltd purchased a new position in shares of Parabilis Medicines during the second quarter worth $955,000. Squarepoint Ops LLC purchased a new stake in shares of Parabilis Medicines in the 2nd quarter valued at $1,327,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Parabilis Medicines in the 2nd quarter valued at $52,572,000. Finally, ICONIQ Capital LLC purchased a new stake in shares of Parabilis Medicines in the 2nd quarter valued at $9,580,000.

Trending Headlines about Parabilis Medicines

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Encouraging Phase 1/2 desmoid tumor results: At the ESMO 2026 Congress, Parabilis reported a 72.2% objective response rate among response-evaluable patients who started treatment at doses of at least 450 mg. The disease control rate was 100% among 46 evaluable patients, with no disease progression. The company also highlighted a favorable safety and tolerability profile, which could support long-term use. Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide
• Positive Sentiment: Clearer regulatory path: Following end-of-Phase 2 discussions, Parabilis said the FDA aligned with its proposed 450 mg weekly induction regimen followed by 300 mg every two weeks for maintenance, a placebo-controlled Phase 3 design, and progression-free survival as the primary endpoint. The company plans to begin the PEDESTAL Phase 3 trial in the first half of 2027, reducing some uncertainty around registrational development. FDA Alignment and Phase 3 Development Plans
• Positive Sentiment: Analyst maintains bullish stance: HC Wainwright reiterated a “Buy” rating and a $40 price target. Its estimates call for losses of $2.10 per share in fiscal 2026 and $1.55 per share in fiscal 2027, indicating continued losses but an expected improvement in profitability. The target is substantially above the stock’s recent trading level. Parabilis Medicines Stock Picked Up by Analysts at HC Wainwright
• Neutral Sentiment: Key timing and execution risks remain: Phase 3 topline results are not expected until 2029, leaving PBLS dependent on future trial enrollment, funding, clinical performance, and regulatory approval. Investors should also note that the company has minimal revenue and recently reported a substantially larger-than-expected quarterly loss.

About Parabilis Medicines

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.